Pharmacotherapy of actinic keratosis

Bibliography

• Smit NP, Vink AA, Kolb RM, Melanin offers protection against induction of cyclobutane pyrimidine dimers and 6-4 photoproducts by UVB in cultured human melanocytes. Photochem Photobiol 2001;74:424-30
   PubMedGoogle Scholar
• Ortonne JP. Photoprotective properties of skin melanin. Br J Dermatol 2002;146:(Suppl 61):7-10
   PubMedGoogle Scholar
• Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6
   PubMed Web of Science ®Google Scholar
• Lookingbill DP, Lookingbill GL, Leppard B. Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program. J Am Acad Dermatol 1995;32:653-8
   PubMed Web of Science ®Google Scholar
• Lehmann AR, Bridges BA. Sunlight-induced cancer: some new aspects and implications of the xeroderma pigmentosum model. Br J Dermatol 1990;122:(Suppl 35):115-19
   PubMedGoogle Scholar
• Lambert WC, Kuo HR, Lambert MW. Xeroderma pigmentosum. Dermatol Clin 1995;13:169-209
   PubMedGoogle Scholar
• Luande J, Henschke CI, Mohammed N. The Tanzanian human albino skin. Natural history. Cancer 1985;55:1823-8
   PubMed Web of Science ®Google Scholar
• Schwartz RA. The actinic keratosis. A perspective and update. Dermatol Surg 1997;23:1009-19
   PubMed Web of Science ®Google Scholar
• Helfand M, Gorman AK, Mahon S, Actinic Keratoses Final Report. US Department of Health & Human Services. Available from: http://www.cms.hhs.gov/coverage/download/8b3-t3.pdf [Last accessed 27 August 2009]
   Google Scholar
• Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. Br J Dermatol 2000;142:1154-9
   PubMed Web of Science ®Google Scholar
• Zagula-Mally ZW, Rosenberg EW, Kashgarian M. Frequency of skin cancer and solar keratoses in a rural southern county as determined by population sampling. Cancer 1974;34:345-9
   PubMedGoogle Scholar
• Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000;115:273-7
   PubMed Web of Science ®Google Scholar
• Giles GG, Marks R, Foley P. Incidence of non-melanocytic skin cancer treated in Australia. Br Med J (Clin Res Ed) 1988;296:13-7
   PubMed Web of Science ®Google Scholar
• Marks R, Jolley D, Lectsas S, Foley P. The role of childhood exposure to sunlight in the development of solar keratoses and non-melanocytic skin cancer. Med J Aust 1990;152:62-6
   PubMed Web of Science ®Google Scholar
• Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom–Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6
   PubMed Web of Science ®Google Scholar
• Blohme I, Larko O. Skin lesions in renal transplant patients after 10 – 23 years of immunosuppressive therapy. Acta Derm Venereol 1990;70:491-4
   PubMed Web of Science ®Google Scholar
• Jeffes EW III, Tang EH. Actinic keratosis. Current treatment options. Am J Clin Dermatol 2000;1:167-79
   PubMedGoogle Scholar
• Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003;139:1313-20
   PubMedGoogle Scholar
• Leffell D. New advances in treating actinic keratoses. Skin Aging 2002;10:31-2
   Google Scholar
• Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795-7
   PubMed Web of Science ®Google Scholar
• Criscione VD, Weinstock MA, Naylor MF, Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2009;115:2523-30
   PubMed Web of Science ®Google Scholar
• Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42:23-4
   PubMed Web of Science ®Google Scholar
• Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000;42:4-7
   PubMed Web of Science ®Google Scholar
• Guidelines for the Management of Actinic Keratoses. © 2004/2005 European Dermatology Forum. Available from: http://www.euroderm.org/content/guidelines_keratoses.htm [Last accessed 27 August 2009]
   Google Scholar
• Drake LA, Ceilley RI, Cornelison RL, Guidelines of care for actinic keratoses. Committee on Guidelines of Care. J Am Acad Dermatol 1995;32:95-8
   PubMedGoogle Scholar
• Suchniak JM, Baer S, Goldberg LH. High rate of malignant transformation in hyperkeratotic actinic keratoses. J Am Acad Dermatol 1997;37:392-4
   PubMedGoogle Scholar
• Ehrig T, Cockerell C, Piacquadio D, Dromgoole S. Actinic keratoses and the incidence of occult squamous cell carcinoma: a clinical-histopathologic correlation. Dermatol Surg 2006;32:1261-5
   PubMedGoogle Scholar
• Berman B, Bienstock L, Kuritzky L, et al; Primary Care Education Consortium; Texas Academy of Family Physicians. Actinic keratoses: sequelae and treatments. Recommendations from a consensus panel. J Fam Pract 2006;55(Suppl):1-8
   Google Scholar
• Quaedvlieg PJ, Tirsi E, Thissen MR, Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006;16:335-9
   PubMed Web of Science ®Google Scholar
• Marks R, Foley P, Goodman G, Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol 1986;115:649-55
   PubMed Web of Science ®Google Scholar
• Balkrishnan R, Cayce KA, Kulkarni AS, Predictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey study. J Dermatolog Treat 2006;17:162-6
   PubMed Web of Science ®Google Scholar
• Berman B, Villa AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol 2006;5:167-73
   PubMedGoogle Scholar
• Nora AB, Panarotto D, Lovatto L, Frequency of counseling for skin cancer prevention by the various specialties in Caxias do Sul. Ann Bras Dermantol 2004;79:45-52
   Google Scholar
• Thompson SC, Jolley D, Marks R. Reduction of solar keratoses by regular sunscreen use. N Engl J Med 1993;329:1147-51
   PubMed Web of Science ®Google Scholar
• Naylor MF, Boyd A, Smith DW, High sun protection factor sunscreens in the suppression of actinic neoplasia. Arch Dermatol 1995;131:170-5
   PubMedGoogle Scholar
• Rigel DS. Photoprotection: a 21st century perspective. Br J Dermatol 2002;146:(Suppl 61):34-7
   PubMedGoogle Scholar
• Moon TE, Levine N, Cartmel B, Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: a randomized, double-blind, controlled trial. Southwest Skin Cancer Prevention Study Group. Cancer Epidemiol Biomarkers Prev 1997;6:949-56
   PubMed Web of Science ®Google Scholar
• Stratton SP, Dorr RT, Alberts DS. The state-of-the-art in chemoprevention of skin cancer. Eur J Cancer 2000;36:1292-7
   PubMedGoogle Scholar
• Einspahr JG, Stratton SP, Bowden GT, Alberts DS. Chemoprevention of human skin cancer. Crit Rev Oncol Hematol 2002;41:269-85
   PubMed Web of Science ®Google Scholar
• Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000;21:525-30
   PubMed Web of Science ®Google Scholar
• Afaq F, Adhami VM, Mukhtar H. Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutat Res 2005;571:153-73
   PubMed Web of Science ®Google Scholar
• Campbell RM, DiGiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther 2006;19:306-14
   PubMed Web of Science ®Google Scholar
• Evans TR, Kaye SB. Retinoids: present role and future potential. Br J Cancer 1999;80:1-8
   PubMedGoogle Scholar
• Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000;130(2S Suppl):479-82S
   Google Scholar
• Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000;16:1084-9
   PubMed Web of Science ®Google Scholar
• Nicholson RC, Mader S, Nagpal S, Negative regulation of the rat stromelysin gene promoter by retinoic acid is mediated by an AP1 binding site. EMBO J 1990;9:4443-54
   PubMed Web of Science ®Google Scholar
• Fanjul A, Dawson MI, Hobbs PD, A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372:107-11
   PubMed Web of Science ®Google Scholar
• Pentland AP, Schoggins JW, Scott GA, Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999;20:1939-44
   PubMed Web of Science ®Google Scholar
• Buckman SY, Gresham A, Hale P, COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998;19:723-9
   PubMed Web of Science ®Google Scholar
• Müller-Decker K, Reinerth G, Krieg P, Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999;82:648-56
   PubMed Web of Science ®Google Scholar
• Fischer SM, Lo HH, Gordon GB, Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999;25:231-40
   PubMed Web of Science ®Google Scholar
• Otley CC, Stasko T, Tope WD, Lebwohl M. Chemoprevention of nonmelanoma skin cancer with systemic retinoids: practical dosing and management of adverse effects. Dermatol Surg 2006;32:562-8
   PubMed Web of Science ®Google Scholar
• Bollag W, Ott F. Retinoic acid: topical treatment of senile or actinic keratoses and basal cell carcinomas. Agents Actions 1970;1:172-5
   PubMedGoogle Scholar
• Barranco VP, Olson RL, Everett MA. Response of actinic keratoses to topical vitamin A acid. Cutis 1970;6:681-5
   Google Scholar
• Bollag W, Ott F. Vitamin A acid in benign and malignant epithelial tumours of the skin. Acta Derm Venereol Suppl (Stockh) 1975;74:163-6
   PubMedGoogle Scholar
• Kurka M, Orfanos CE, Pullmann H. Vitamin A acid for the topical management of epithelial neoplasms. Combination with 5-fluorouracil. Hautarzt 1978;29:313-18
   PubMedGoogle Scholar
• Kleinsmith DA, Thomas L. Retinoic acid in the treatment of actinic keratoses. J Dermatol Surg Oncol 1988;14:103
   Google Scholar
• Misiewicz J, Sendagorta E, Golebiowska A, Topical treatment of multiple actinic keratoses of the face with arotinoid methyl sulfone (Ro 14-9706) cream versus tretinoin cream: a double-blind, comparative study. J Am Acad Dermatol 1991;24:448-51
   PubMed Web of Science ®Google Scholar
• Alirezai M, Dupuy P, Amblard P, Clinical evaluation of topical isotretinoin in the treatment of actinic keratoses. J Am Acad Dermatol 1994;30:447-51
   PubMed Web of Science ®Google Scholar
• McCann PP, Bitonti, AJ, Pegg AE. Inhibition of polyamine metabolism and the consequent effects on cell proliferation. In: Wattenberg L, editor, Cancer Chemoprevention. Boca Raton, FL: CRC Press; 1992. p. 531-9
   Google Scholar
• Pegg AE. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. Cancer Res 1988;48:759-74
   PubMed Web of Science ®Google Scholar
• Pegg AE, Madhubala R, Karneji T, Control of ornithine decarboxylase activity in alpha-difluoromethylornithine-resistant L1210 cells by polyamines and synthetic analogues. J Biol Chem 1988;263:11008-14
   PubMed Web of Science ®Google Scholar
• Alberts DS, Dorr RT, Einspahr JG, Chemoprevention of human actinic keratoses by topical 2-(Difluoromethyl)-dl-ornithine. Cancer Epidemiol Biomarkers Prev 2000;9:1281-6
   PubMed Web of Science ®Google Scholar
• Einspahr JG, Nelson MA, Saboda K, Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. Clin Cancer Res 2002;8:149-55
   PubMedGoogle Scholar
• Alberts DS. Phase IIB randomized, double-blinded, placebo controlled study to evaluate the safety and efficacy of topical difluoromethylornithine (DFMO) with and without a topical corticosteroid cream (triamcinolone 0.1%) in the therapy of actinic keratoses (AK) on the forearms. ClinicalTrials. gov Identifier: NCT00021294. Available from: http://clinicaltrials.gov/ct2/show/NCT00021294 [Last accessed on 27 August 2009]
   Google Scholar
• Crowell PL. Prevention and therapy of cancer by dietary monoterpenes. J Nutr 1999;129:775-8S
   PubMed Web of Science ®Google Scholar
• Belanger JT. Perillyl alcohol: applications in oncology. Altern Med Rev 1998;3:448-57
   PubMedGoogle Scholar
• Barthelman M, Chen W, Gensler HL, Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998;58:711-16
   PubMed Web of Science ®Google Scholar
• Chaudhary SC, Alam MS, Siddiqui MS, Athar M. Perillyl alcohol attenuates Ras-ERK signaling to inhibit murine skin inflammation and tumorigenesis. Chem Biol Interact 2009;179:145-53, [Epub 2008 Dec 31]
   PubMed Web of Science ®Google Scholar
• Stratton SP, Saboda KL, Myrdal PB, Phase 1 study of topical perillyl alcohol cream for chemoprevention of skin cancer. Nutr Cancer 2008;60:325-30
   PubMed Web of Science ®Google Scholar
• Stratton S. Phase 2a randomized, placebo-controlled, double-blind trial of topical perillyl alcohol in sun damaged skin. ClinicalTrials. gov Identifier: NCT00608634. Available from: http://clinicaltrials.gov/ct2/show/NCT00608634 [Last accessed on 27 August 2009]
   Google Scholar
• Cafardi JA, Elmets CA. T4 endonuclease V: review and application to dermatology. Expert Opin Biol Ther 2008;8:829-38
   PubMed Web of Science ®Google Scholar
• Yarosh D, Klein J, O’Connor A, Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001;357:926-9
   PubMed Web of Science ®Google Scholar
• A randomized, double-blind, multicenter clinical study to test the safety and efficacy of T4N5 liposome lotion on patients with xeroderma pigmentosum in the protection against actinic keratosis. ClinicalTrials.gov Identifier: NCT00002811. Available from: http://clinicaltrials.gov/ct2/show/NCT00002811 [Last accessed 27 August 2009]
   Google Scholar
• A Phase IIb randomized, double-blind, placebo-controlled clinical trial of topical bacteriophage t4 endonuclease v in renal allograft recipients with a history of non-melanoma skin cancer. ClinicalTrials.gov Identifier: NCT00089180. Available from: http://clinicaltrials.gov/ct2/show/NCT00089180 [Last accessed 27 August 2009]
   Google Scholar
• Reagan-Shaw S, Mukhtar H, Ahmad N. Resveratrol imparts photoprotection of normal cells and enhances the efficacy of radiation therapy in cancer cells. Photochem Photobiol 2008;84:415-21
   PubMed Web of Science ®Google Scholar
• Aziz MH, Reagan-Shaw S, Wu J, Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease? FASEB J 2005;19:1193-5
   PubMed Web of Science ®Google Scholar
• Baliga MS, Katiyar SK. Chemoprevention of photocarcinogenesis by selected dietary botanicals. Photochem Photobiol Sci 2006;5:243-53
   PubMed Web of Science ®Google Scholar
• Elmets CA, Singh D, Tubesing K, Cutaneous photoprotection from ultraviolet injury by green tea polyphenols. J Am Acad Dermatol 2001;44:425-32
   PubMed Web of Science ®Google Scholar
• Fryer MJ. Evidence for the photoprotective effects of vitamin E. Photochem Photobiol 1993;58:304-12
   PubMed Web of Science ®Google Scholar
• Rhie G, Shin MH, Seo JY, Aging- and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo. J Invest Dermatol 2001;117:1212-17
   PubMed Web of Science ®Google Scholar
• Gensler HL, Magdaleno M. Topical vitamin E inhibition of immunosuppression and tumorigenesis induced by ultraviolet irradiation. Nutr Cancer 1991;15:97-106
   PubMed Web of Science ®Google Scholar
• Foote JA, Ranger-Moore JR, Einspahr JG, Chemoprevention of human actinic keratoses by topical DL-a-tocopherol. Cancer Prev Res 2009;2:394-400
   PubMedGoogle Scholar
• Halpern AC, Hanson LJ. Awareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol 2004;43:638-42
   PubMedGoogle Scholar
• Neidecker MV, Davis-Ajami ML, Balkrishnan R, Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics 2009;27:451-64
   PubMedGoogle Scholar
• Lubritz RR, Smolewski SA. Cryosurgery cure rates of actinic keratosis. J Am Acad Dermatol 1982;7:631-2
   PubMed Web of Science ®Google Scholar
• Thai KE, Fergin P, Freeman M, A prospective study of the use of cryosurgery for the treatment of actinic keratoses. Int J Dermatol 2004;43:687-92
   PubMed Web of Science ®Google Scholar
• de Berker D, McGregor JM, Hughes BR, Guidelines for the management of actinic keratoses. Br J Dermatol 2007;156:222-30
   PubMed Web of Science ®Google Scholar
• Krawtchenko N, Roewert-Huber J, Ulrich M, A randomised study of topical 5% imiquimod vs. topical 5-fluorouracil vs. cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 2007;157:(Suppl 2):34-40
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Karrer S, Radakovic-Fijan S, Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-62
   PubMed Web of Science ®Google Scholar
• Chiarello SE. Cryopeeling (extensive cryosurgery) for treatment of actinic keratosis: an update and comparison. Dermatol Surg 2000;26:728-32
   PubMed Web of Science ®Google Scholar
• Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. Plast Reconstr Surg 1987;80:47-54
   PubMedGoogle Scholar
• Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. Am Acad Dermatol 2000;42:8-10
   PubMed Web of Science ®Google Scholar
• Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000;42:25-8
   PubMedGoogle Scholar
• Fu W, Cockerell C. The actinic (solar) keratosis: a 21st-century perspective. Arch Dermatol 2003;139:66-70
   PubMed Web of Science ®Google Scholar
• An KP, Ratner D. Surgical management of cutaneous malignancies. Clin Dermatol 2001;19:305-20
   PubMedGoogle Scholar
• Geisse JK. Comparison of treatment modalities for squamous cell carcinoma. Clin Dermatol 1995;13:621-6
   PubMedGoogle Scholar
• David LM, Lask GP, Glassberg E, Laser abrasion for cosmetic and medical treatment of facial actinic damage. Cutis 1989;43:583-7
   PubMedGoogle Scholar
• Iyer S, Friedli A, Bowes L, Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cnacer. Lasers Surg Med 2004;34:114-19
   PubMed Web of Science ®Google Scholar
• Ostertag JU, Quaedvlieg P, Neumann M, Krekels G. Recurrence rates and long-term follow-up after laser resurfacing as a treatment for widespread actinic keratoses in the face and on the scalp. Dermatol Surg 2006;32:261-7
   PubMed Web of Science ®Google Scholar
• Fulton JE, Rahimi AD, Helton P, Disappointing results following resurfacing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg 1999;25:729-32
   PubMed Web of Science ®Google Scholar
• Orenstein A, Goldan O, Weissman O, A new modality in the treatment of actinic cheilitis using the Er:YAG laser. J Cosmet Laser Ther 2007;9:23-5
   PubMedGoogle Scholar
• Wollina U, Konrad H, Karamfilov T. Treatment of common warts and actinic keratoses by Er: YAG laser. J Cutan Laser Ther 2001;3:63-6
   PubMedGoogle Scholar
• Jiang SB, Levine VJ, Nehal KS, Er: YAG laser for the treatment of actinic keratoses. Dermatol Surg 2000;26:437-40
   PubMed Web of Science ®Google Scholar
• Coleman WP III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg 1996;22:17-21
   PubMedGoogle Scholar
• Harmon CB. Dermabrasion. Dermatol Clin 2001;19:439-42, viii
   PubMedGoogle Scholar
• Dermabrasion. In: Fewkes JL, Cheney ML, Pollack SV, editors. Illustrated Atlas of Cutaneous Surgery. 1st edition. Philadelphia, PA: J.B. Lippincott Co.; 1992. p. 26.1-26.11
   Google Scholar
• Monheit GD. Medium-depth chemical peels. Dermatol Clin 2001;19:413-25, vii
   PubMedGoogle Scholar
• Coleman WP III. Dermal peels. Dermatol Clin 2001;19:405-11
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Uede K, Yonei N, Expression of tenascin and human B-1 integrin in the skin peeled with phenol or trichloracetic acid. Aesthetic Dermatol 2003;13:17-24
   Google Scholar
• Yamamoto Y, Uede K, Ueda M, Characterization of monoclonal anti-human skin basal cell antibody 3B 4-6 and its reactivity to the skin peeled with phenol or trichloracetic acid (TCA). Aesthetic Dermatol 2002;12:70-6
   Google Scholar
• Yamamoto Y, Yonei N, Kaminaka C, Effects of phenol peeling on dermal endothelial cells. J Dermatol Sci 2004;35:158-61
   PubMedGoogle Scholar
• Yamamoto Y, Uede K, Otani T, Different apoptotic patterns observed in tissues damaged by phenol and TCA peels. J Dermatol Sci 2006;2(Suppl):75-81
   Google Scholar
• Stuzin JM. Phenol peeling and the history of phenol peeling. Clin Plast Surg 1998;25:1-19
   PubMedGoogle Scholar
• Kaminaka C, Yamamoto Y, Yonei N, Phenol peels as a novel therapeutic approach for actinic keratosis and Bowen disease: prospective pilot trial with assessment of clinical, histologic, and immunohistochemical correlations. J Am Acad Dermatol 2009;60:615-25
   PubMedGoogle Scholar
• Imbertson LM, Beaurline JM, Couture AM, Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463. J Invest Dermatol 1998;110:734-9
   PubMed Web of Science ®Google Scholar
• Wagner TL, Ahonen CL, Couture AM, Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod. Cell Immunol 1999;191:10-9
   PubMed Web of Science ®Google Scholar
• Hemmi H, Kaisho T, Takeuchi O, Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200
   PubMed Web of Science ®Google Scholar
• Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators – progress towards treating inflammation, infection, and cancer. Lancet Infect Dis 2001;1:189-98
   PubMedGoogle Scholar
• Kono T, Kondo S, Pastore S, Effects of a novel topical immunomodulator, imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res 1994;13:71-6
   PubMedGoogle Scholar
• Arany I, Tyring SK, Stanley MA, Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res 1999;43:55-63
   PubMed Web of Science ®Google Scholar
• Clifford JL, Walch E, Yang X, Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 2002;8:2067-72
   PubMedGoogle Scholar
• Tyring S, Conant M, Marini M, Imiquimod; an international update on therapeutic uses in dermatology. Int J Dermatol 2002;41:810-16
   PubMed Web of Science ®Google Scholar
• Ooi T, Barnetson RS, Zhuang L, Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. Br J Dermatol 2006;154:72-8
   PubMedGoogle Scholar
• Schön M, Bong AB, Drewniok C, Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003;95:1138-49
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Meyer T, Benninghoff B, A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002;138:1498-502
   PubMed Web of Science ®Google Scholar
• Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: an open-label trial. J Am Acad Dermatol 2002;47:571-7
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Dinehart S, Whiting D, Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol 2004;50:714-21
   PubMed Web of Science ®Google Scholar
• Szeimies RM, Gerritsen MJ, Gupta G, Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004;51:547-55
   PubMed Web of Science ®Google Scholar
• Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005;9:209-14
   PubMed Web of Science ®Google Scholar
• Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006;55:537-8
   PubMed Web of Science ®Google Scholar
• Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006;126:1251-5
   PubMed Web of Science ®Google Scholar
• Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004;140:1542
   PubMed Web of Science ®Google Scholar
• Rivers JK, Rosoph L, Provost N, Open-label study to assess the safety and efficacy of imiquimod 5% cream applied once daily three times per week in cycles for treatment of actinic keratoses on the head. J Cutan Med Surg 2008;12:97-101
   PubMedGoogle Scholar
• Stockfleth E, Sterry W, Carey-Yard M, Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol 2007;157:(Suppl 2):41-6
   PubMed Web of Science ®Google Scholar
• Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007;157:133-41
   PubMed Web of Science ®Google Scholar
• Korman N, Moy R, Ling M, Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005;141:467-73
   PubMed Web of Science ®Google Scholar
• Zeichner JA, Stern DW, Uliasz A, Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. J Am Acad Dermatol 2009;60:59-62
   PubMed Web of Science ®Google Scholar
• Ulrich C, Bichel J, Euvrard S, Topical immunomodulation under systemic immunosuppression: results of a multicentre, randomized, placebo-controlled safety and efficacy study of imiquimod 5% cream for the treatment of actinic keratoses in kidney, heart, and liver transplant patients. Br J Dermatol 2007;157:(Suppl 2):25-31
   PubMed Web of Science ®Google Scholar
• Pearlman DL. Weekly pulse dosing: effective and comfortable topical 5-fluorouracil treatment of multiple facial actinic keratoses. J Am Acad Dermatol 1991;25:665-7
   PubMedGoogle Scholar
• Yentzer B, Hick J, Williams L, Adherence to a topical regimen of 5-fluorouracil, 0.5%, cream for the treatment of actinic keratoses. Arch Dermatol 2009;145:203-5
   PubMedGoogle Scholar
• Weiss J, Menter A, Hevia O, Effective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeks. Cutis 2002;70(2 Suppl):22-9
   PubMedGoogle Scholar
• Loven K, Stein L, Furst K, Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. Clin Ther 2002;24:990-1000
   PubMed Web of Science ®Google Scholar
• Price NM. The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. J Drugs Dermatol 2007;6:778-81
   PubMedGoogle Scholar
• Tanghetti E, Werschler P. Comparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalp. J Drugs Dermatol 2007;6:144-7
   PubMedGoogle Scholar
• An KP, Athar M, Tang X, Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002;76:73-80
   PubMed Web of Science ®Google Scholar
• Denkert C, Kobel M, Berger S, Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001;61:303-8
   PubMed Web of Science ®Google Scholar
• Rivers JK, Arlette J, Shear N, Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002;146:94-100
   PubMed Web of Science ®Google Scholar
• Mastrolonardo M. Topical diclofenac 3% gel plus cryotherapy for treatment of multiple and recurrent actinic keratoses. Clin Exp Dermatol 2009;34:33-5
   PubMed Web of Science ®Google Scholar
• Smith SR, Morhenn VB, Piacquadio DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% 5-fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol 2006;5:156-9
   PubMedGoogle Scholar
• Kose O, Koc E, Erbil AH, Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis. J Dermatolog Treat 2008;19:159-63
   PubMed Web of Science ®Google Scholar
• Buggiani G, Troiano M, Rossi R, Photodynamic therapy: off-label and alternative use in dermatological practice. Photodiagnosis Photodyn Ther 2008;5:134-8
   PubMed Web of Science ®Google Scholar
• Wang XL, Wang HW, Guo MX, Treatment of skin cancer and pre-cancer using topical ALA-PDT – a single hospital experience. Photodiagnosis Photodyn Ther 2008;5:127-33
   PubMedGoogle Scholar
• Touma D, Yaar M, Whitehead S, A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004;140:33-40
   PubMedGoogle Scholar
• Braathen LR, Szeimies RM, Basset-Seguin N, Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International society for photodynamic therapy in dermatology, 2005. J Am Acad Dermatol 2007;56:125-43
   PubMed Web of Science ®Google Scholar
• Piacquadio DJ, Chen DM, Farber HF, Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:41-6
   PubMed Web of Science ®Google Scholar
• Tierney E, Barker A, Ahdout J, Photodynamic therapy for the treatment of cutaneous neoplasia, inflammatory disorders, and photoaging. Dermatol Surg 2009;35:725-46
   PubMed Web of Science ®Google Scholar
• Dusa Pharmaceuticals. Levulan Kerastick (aminolevulinic acid HCL) for topical solution, 20%. Product Insert; 2004
   Google Scholar
• Smith S, Piacquadio D, Morhenn V, Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003;2:629-35
   PubMedGoogle Scholar
• Pariser DM, Lowe NJ, Stewart DM, Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-32
   PubMed Web of Science ®Google Scholar
• Tarstedt M, Rosdahl I, Berne B, A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005;85:424-8
   PubMed Web of Science ®Google Scholar
• Freeman M, Vinciullo C, Francis D, A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14:99-106
   PubMedGoogle Scholar
• Sotiriou E, Apalla Z, Maliamani F, Intraindividual, right-left comparison of topical 5-aminolevulinic acid photodynamic therapy vs. 5% imiquimod cream for actinic keratoses on the upper extremities. J Eur Acad Dermatol Venereol 2009;23:1061-5
   PubMed Web of Science ®Google Scholar
• Shaffelburg M. Treatment of actinic keratoses with sequential use of photodynamic therapy; and imiquimod 5% cream. J Drugs Dermatol 2009;8:35-9
   PubMed Web of Science ®Google Scholar
• Gupta AK. The management of actinic keratoses in the United States with topical fluorouracil: a pharmacoeconomic evaluation. Cutis 2002;70(2 Suppl):30-6
   PubMedGoogle Scholar
• Muston D, Downs A, Rives V. An economic evaluation of topical treatments for actinic keratosis. J Dermatolog Treat 2009:1-10
   Google Scholar
• Caekelbergh K, Annemans L, Lambert J, Roelandts R. Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. Br J Dermatol 2006;155:784-90
   PubMed Web of Science ®Google Scholar
• Ogbourne SM, Suhrbier A, Jones B, Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 2004;64:2833-9
   PubMed Web of Science ®Google Scholar
• Siller G, Gebauer K, Welburn P, PEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multicentre, phase IIa study. Australas J Dermatol 2009;50:16-22
   PubMed Web of Science ®Google Scholar
• Challacombe JM, Suhrbier A, Parsons PG, Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 2006;177:8123-32
   PubMed Web of Science ®Google Scholar
• Anderson L, Schmieder GJ, Werschler WP, Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009;60:934-43
   PubMed Web of Science ®Google Scholar
• Testerman TL, Gerster JF, Imbertson LM, Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukoc Biol 1995;58:365-72
   PubMed Web of Science ®Google Scholar
• Tomai MA, Gibson SJ, Imbertson LM, Immunomodulating and antiviral activities of the imidazoquinoline S-28463. Antiviral Res 1995;28:253-64
   PubMed Web of Science ®Google Scholar
• Jones T. Resiquimod 3M. Curr Opin Investig Drugs 2003;4:214-18
   PubMedGoogle Scholar
• Szeimies RM, Bichel J, Ortonne JP, A phase II dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol 2008;159:205-10
   PubMed Web of Science ®Google Scholar
• Jäger S, Laszczyk MN, Scheffler A. A preliminary pharmacokinetic study of betulin, the main pentacyclic triterpene from extract of outer bark of birch (Betulae alba cortex). Molecules 2008;13:3224-35
   PubMed Web of Science ®Google Scholar
• Krasutsky PA. Birch bark research and development. Nat Prod Rep 2006;23:919-42
   PubMed Web of Science ®Google Scholar
• Huyke C, Reuter J, Rödig M, Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 2009;7:128-33
   PubMed Web of Science ®Google Scholar
• Swanson N, Rosen, T Berman B, Optimizing imiquimod for treating actinic keratosis of the full face or balding scalp: imiquimod 2.5% and 3.75% applied daily for two 2-week or 3-week cycles. Poster presented at the 12th World Congress on Cancers of the Skin, 3 – 6 May 2009, Tel-Aviv, Israel
   Google Scholar